Provided by Tiger Trade Technology Pte. Ltd.

Evaxion Biotech A/S

3.52
-0.0700-1.95%
Post-market: 3.590.0700+1.99%16:17 EDT
Volume:30.25K
Turnover:104.84K
Market Cap:29.23M
PE:-2.93
High:3.58
Open:3.58
Low:3.31
Close:3.59
52wk High:12.15
52wk Low:1.20
Shares:8.30M
Float Shares:5.53M
Volume Ratio:1.64
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2027
EPS(LYR):-1.2027
ROE:-100.18%
ROA:-28.23%
PB:1.72
PE(LYR):-2.93

Loading ...

Evaxion a/S: Birgitte RØNØ, Who Has Served as Interim CEO, Will Continue in Her Role as Chief Scientific Officer

THOMSON REUTERS
·
Oct 27, 2025

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

GlobeNewswire
·
Oct 27, 2025

European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading

MT Newswires Live
·
Oct 24, 2025

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

MT Newswires Live
·
Oct 21, 2025

Evaxion Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 20, 2025

European Equities Traded in the US as American Depositary Receipts Down in Friday Trading, Up for Week

MT Newswires Live
·
Oct 17, 2025

Evaxion Biotech reports 75% ORR rate in Phase 2 trial of EVX-01

TIPRANKS
·
Oct 17, 2025

BRIEF-Evaxion Reports 75% Objective Response Rate In Phase 2 Trial With Ai-Designed Personalized Cancer Vaccine EVX-01

Reuters
·
Oct 17, 2025

Evaxion a/S - Immune Activation Observed in All Patients With 81% of Evx-01'S Vaccine Targets Triggering a Specific Response

THOMSON REUTERS
·
Oct 17, 2025

Evaxion Reports 75% Objective Response Rate in Phase 2 Trial With AI-Designed Personalized Cancer Vaccine Evx-01

THOMSON REUTERS
·
Oct 17, 2025

Evaxion a/S - 75% Objective Response Rate as 12 Out of 16 Advanced Melanoma Patients Had Objective Clinical Responses

THOMSON REUTERS
·
Oct 17, 2025

Evaxion a/S: Treatment Was Well Tolerated in Phase 2 Trial

THOMSON REUTERS
·
Oct 17, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires Live
·
Oct 16, 2025

Evaxion Biotech trading resumes

TIPRANKS
·
Oct 15, 2025

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires Live
·
Oct 13, 2025

Evaxion A/S to Present Two-Year Phase 2 Data on AI-Designed Personalized Cancer Vaccine EVX-01 at ESMO Congress 2025

Reuters
·
Oct 13, 2025

European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading, Down 2.8% for Week

MT Newswires Live
·
Oct 10, 2025

Evaxion Unveils Automated AI Vaccine Design Module Promising Faster, Higher-Quality Immunization Solutions

Reuters
·
Oct 08, 2025

European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading

MT Newswires Live
·
Oct 07, 2025

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

GlobeNewswire
·
Oct 03, 2025